Response to the letter by Prof Jonathan Deeks to the Lancet EClinicalMedicine editor

Documenti analoghi

• Corrigendum to ‘Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study.’ [EClinicalMedicine 59 (2023) 101981]
  di: Yuming Sun, et al.
  Pubblicazione: (2023-08-01)
• Corrigendum to “Nitazoxanide superiority to placebo to treat moderate COVID-19 – A Pilot prove of concept randomized double-blind clinical trial.” [EClinicalMedicine 37 (2021) 100981]
  di: Vinicius Fontanesi Blum, MD, MSc, et al.
  Pubblicazione: (2021-11-01)
• Corrigendum to “Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis” [EClinicalMedicine 55 (2022) 101795]
  di: Zhiwen Fu, et al.
  Pubblicazione: (2023-04-01)
• Impact of national-scale targeted point-of-care symptomatic lateral flow testing on trends in COVID-19 infections and hospitalisations during the second epidemic wave in Austria
  di: Reitzinger, S, et al.
  Pubblicazione: (2023)
• Impact of national-scale targeted point-of-care symptomatic lateral flow testing on trends in COVID-19 infections, hospitalisations and deaths during the second epidemic wave in Austria (REAP3)
  di: Stephanie Reitzinger, et al.
  Pubblicazione: (2023-03-01)